PARP1 and triple-negative breast carcinoma: AZ31 (5) combined with irinotecan enhances antitumor effects in colorectal cancer models, while its synergy with the PARP inhibitor olaparib shows increased cytotoxicity in triple-negative breast cancer and HeLa cells.